EORTC trial opens for patients with differentiated or medullary thyroid cancer progressing after first line therapy
20 May 2014
In the European Union there were an estimated 36,900 new cases of thyroid cancer and 3600 deaths in 2012. Although thyroid cancer is rare, it is the most common endocrine cancer. Among thyroid tumors, the vast majority are differentiated carcinomas (approximately 90%), and medullary cancers make up between 5 and 10%.
Treatment for patients with early stage differentiated thyroid cancer is thyroidectomy, and radioiodine treatment is administered postoperatively to patients with persistent or recurrent disease. Patients with radioiodine refractory disease can be treated with cytotoxic chemotherapy, with limited benefit, or tyrosine kinase inhibitors. Unfortunately, the majority of these patients will progress.
Surgery is also the primary treatment for patients with medullary thyroid cancer. Postoperative radiation therapy may also be prescribed for patients who underwent incomplete resection or removal or have positive margins. Systemic therapy with traditional cytotoxic agents is an option for patients with progressive or metastatic disease.
There is a need for improved treatment for patients with thyroid cancer who have progressed on first line therapy. Prof. Martin Schlumberger of the Gustave Roussy in Villejuif, France, and coordinator of this study points out, “Nintedanib inhibits the vascular endothelial (VEGF), fibroblast (FGF), and platelet derived (PDGF) growth factor receptors. As such, we think that this targeted agent could stop further tumor growth and prevent related tumor escape mechanisms. Nintedanib could help patients who have progressed on compounds that block only one of these three growth factor receptors.”
EORTC trial 1209 will explore the safety and efficacy of nintedanib (BIBF1120) as second line therapy for patients with either differentiated or medullary thyroid cancer progressing after first line therapy. Patients enrolled in this phase II trial will be randomized in a two to one ratio in favor of the experimental arm.
This phase II trial plans to accrue a total of 143 patients who progress after the first line of treatment; 75 patients in the group with differentiated thyroid cancer, and 68 patients in the group with medullary thyroid cancer. Patients in the experimental arm will receive nintedanib and patients in the control arm will receive matching placebo. Patients will continue to receive treatment until disease progression (according to RECIST 1.1) is documented, toxicity is unacceptable, or the patient decides to cease treatment. The primary endpoint of this trial is progression-free survival. Upon disease progression treatment will be unblinded and patients in placebo arm will be offered the option of receiving nintedanib up to further progression.
EORTC trial 1209 will be conducted in 36 sites located in nine countries: Belgium, Denmark, France, Germany, Italy, Poland, Spain, The Netherlands, and the United Kingdom. This trial is coordinated by the EORTC Endocrine Tumors Task Force and supported by an Educational Grant from Boehringer Ingelheim.
For more information please contact: www.eortc.org/contact
John Bean, PhD
EORTC, Medical Science Writer
Related News
Meet the new EORTC Board
9 Jul 2024
We are pleased to announce the release of the EORTC 2023 Annual Report
17 Jun 2024
Dr Denis Lacombe, EORTC CEO, appointed stakeholder co-chair of ACT EU advisory group
24 May 2024
Clinical Trials Day 2024: a Q&A on pragmatic clinical trials
20 May 2024
EORTC/EMA workshop suggests an international way forward for treatment optimisation studies
8 May 2024
EORTC’s Participation at the ESTRO Congress 2024
29 Apr 2024
EORTC: Advancing research and treatment for rare cancers
29 Feb 2024
EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration
22 Feb 2024
Appointment of Malte Peters as EORTC Strategic Alliance Officer
9 Feb 2024
Unique series of workshops in partnership with the European Medicines Agency (EMA)
7 Feb 2024